DK1412486T3 - Fremgangsmåde til virusformering - Google Patents

Fremgangsmåde til virusformering

Info

Publication number
DK1412486T3
DK1412486T3 DK02740758T DK02740758T DK1412486T3 DK 1412486 T3 DK1412486 T3 DK 1412486T3 DK 02740758 T DK02740758 T DK 02740758T DK 02740758 T DK02740758 T DK 02740758T DK 1412486 T3 DK1412486 T3 DK 1412486T3
Authority
DK
Denmark
Prior art keywords
virus propagation
virus
propagation
Prior art date
Application number
DK02740758T
Other languages
Danish (da)
English (en)
Inventor
Karl Heller
Paul Howley
Ingmar Raethe
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1412486(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK1412486T3 publication Critical patent/DK1412486T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C07K14/07—Vaccinia virus; Variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
DK02740758T 2001-07-18 2002-07-02 Fremgangsmåde til virusformering DK1412486T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101122 2001-07-18
PCT/EP2002/007280 WO2003008533A2 (en) 2001-07-18 2002-07-02 Method for virus propagation

Publications (1)

Publication Number Publication Date
DK1412486T3 true DK1412486T3 (da) 2008-03-10

Family

ID=8160630

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02740758T DK1412486T3 (da) 2001-07-18 2002-07-02 Fremgangsmåde til virusformering

Country Status (19)

Country Link
US (1) US6924137B2 (enExample)
EP (1) EP1412486B1 (enExample)
JP (2) JP4700907B2 (enExample)
KR (1) KR100908377B1 (enExample)
CN (1) CN100513560C (enExample)
AU (1) AU2002314201B2 (enExample)
BR (2) BRPI0211276B1 (enExample)
CA (1) CA2450206C (enExample)
DE (1) DE60223812T2 (enExample)
DK (1) DK1412486T3 (enExample)
EA (1) EA006628B1 (enExample)
HU (1) HUP0400393A3 (enExample)
IL (2) IL158927A0 (enExample)
MX (1) MXPA04000326A (enExample)
NO (1) NO339056B1 (enExample)
NZ (1) NZ529914A (enExample)
PL (1) PL205926B1 (enExample)
UA (1) UA82466C2 (enExample)
WO (1) WO2003008533A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1335987T4 (en) * 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara
WO2004022729A1 (en) * 2002-09-05 2004-03-18 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
TWI638829B (zh) 2012-07-10 2018-10-21 法商傳斯堅公司 分枝桿菌抗原疫苗
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US10913063B2 (en) * 2016-07-12 2021-02-09 EMULATE, Inc. Removing bubbles in a microfluidic device
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
SG11201912429RA (en) 2017-06-21 2020-01-30 Transgene Sa Personalized vaccine
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
AU2024241503A1 (en) 2023-03-17 2025-08-14 Albert-Ludwigs-Universität Freiburg Hbv antigen formulation for treating hepatitis b
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384845A1 (fr) * 1976-08-05 1978-10-20 Anvar Vaccin contre la myxomatose et nouvelle souche virale utilisee
JPS60202827A (ja) * 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
WO1997012032A1 (en) * 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (en) * 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
DK1335987T4 (en) * 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara

Also Published As

Publication number Publication date
PL366897A1 (en) 2005-02-07
US6924137B2 (en) 2005-08-02
EP1412486B1 (en) 2007-11-28
BRPI0211276B1 (pt) 2018-12-04
JP2011078424A (ja) 2011-04-21
EA006628B1 (ru) 2006-02-24
KR100908377B1 (ko) 2009-07-20
EP1412486A2 (en) 2004-04-28
EA200400195A1 (ru) 2004-06-24
US20040234950A1 (en) 2004-11-25
JP4700907B2 (ja) 2011-06-15
WO2003008533A2 (en) 2003-01-30
CN1533433A (zh) 2004-09-29
BR0211276A (pt) 2004-08-03
HK1066245A1 (zh) 2005-03-18
KR20040018474A (ko) 2004-03-03
HUP0400393A3 (en) 2004-10-28
UA82466C2 (uk) 2008-04-25
DE60223812T2 (de) 2008-11-13
AU2002314201B2 (en) 2006-09-21
CN100513560C (zh) 2009-07-15
NZ529914A (en) 2005-03-24
MXPA04000326A (es) 2005-03-07
NO339056B1 (no) 2016-11-07
NO20040158L (no) 2004-01-13
JP5154632B2 (ja) 2013-02-27
WO2003008533A3 (en) 2004-01-08
PL205926B1 (pl) 2010-06-30
JP2004535203A (ja) 2004-11-25
CA2450206C (en) 2012-08-21
IL158927A (en) 2009-09-01
CA2450206A1 (en) 2003-01-30
DE60223812D1 (de) 2008-01-10
IL158927A0 (en) 2004-05-12
HUP0400393A2 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
DK1412486T3 (da) Fremgangsmåde til virusformering
NO20025814L (no) Fremgangsmåte ved brönnfullföring
ATE370938T1 (de) Pro-pharmakon von cox-2-inhibitoren
NO20035426L (no) Fremgangsmate ved administrering av anti-TNF-D-antistoff
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
NO20040353L (no) Ny terapeutsk metode
DK1350765T3 (da) Fremgangsmåde til fremstilling af jernoxider
FI20010558L (fi) Kappaleiden paikannus
ATE502118T1 (de) Amplifizierungsverfahren
DK1353923T3 (da) Forbedret fremgangsmåde til syntese af carbapenem
NO331195B1 (no) Fremgangsmate for fremstilling av halogen-substituerte monosulfider og deres hydroksymonosulfid-evkivalenter som mellomprodukter.
DK1294659T3 (da) Fremgangsmåde til isolering af katamin
IS7069A (is) Aðferð til að framleiða zaleplon
IS6884A (is) Aðferðir við að nýta líffræðilegan fjölbreytileika
EP1463521A4 (en) INHIBITOR OF GP41
ITMI20010954A0 (it) Procedimento di iodurazione
DE60226093D1 (de) Urmedium-Reinigungsmethode
DE60331820D1 (de) Beseitigung von verstopfungen von rohrleitungen
FI20010865L (fi) Sahausmenetelmä
SE0104471D0 (sv) New method
FIU20010453U0 (fi) Marinadin valmistusmenetelmä
SE0104249D0 (sv) Method of treatment
NO20011136D0 (no) FremgangsmÕte ved byggbehandling
DK1319049T3 (da) Grunding af stål
SE0101479D0 (sv) Method